MX2015000760A - Sistema de suministro de farmaco gastro - retentivo. - Google Patents

Sistema de suministro de farmaco gastro - retentivo.

Info

Publication number
MX2015000760A
MX2015000760A MX2015000760A MX2015000760A MX2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A
Authority
MX
Mexico
Prior art keywords
drug delivery
delivery systems
floating
floating drug
fdds
Prior art date
Application number
MX2015000760A
Other languages
English (en)
Inventor
Hendrik Jan Cornelis Meijerink
Lekhram Changoer
Anko Cornelus Eissens
Henderik Willem Frijlink
Willem Blom
Marinella Regina Visser
Original Assignee
Apet Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2012/050511 external-priority patent/WO2013009186A1/en
Application filed by Apet Holding B V filed Critical Apet Holding B V
Publication of MX2015000760A publication Critical patent/MX2015000760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a sistemas de suministro de fármaco flotantes (FDDS, por sus siglas en inglés) que proporcionan soluciones a los problemas particulares encontrados a menudo con sistemas de suministro de fármaco flotantes descritos en el campo. Tal problema generalmente reconocido es la vulnerabilidad de los sistemas, especialmente el daño al compartimiento llenado con gas que lo hace inaccesible al agua para impartir su capacidad para flotar, finalmente resultando en un tiempo de residencia gástrica insuficiente. La invención, en un aspecto, proporciona un FDDS auto-reparable que mantiene su capacidad de flotación después de dañarse. Los sistemas de suministro de fármaco flotantes de la invención, adicionalmente, permiten la incorporación de cargas altas de ingredientes activos. Los sistemas de suministro de fármaco flotantes pueden diseñarse de tal manera que la liberación del ingrediente activo desde el sistema ocurre completamente independiente del pH del fluido que rodea el sistema. Adicionalmente, el procedimiento de fabricación del sistema de suministro de fármaco flotante de la invención es sencillo y directo, y por lo tanto económicamente atractivo.
MX2015000760A 2012-07-16 2013-07-15 Sistema de suministro de farmaco gastro - retentivo. MX2015000760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2012/050511 WO2013009186A1 (en) 2011-07-14 2012-07-16 Nicotinamide compositions and the therapeutic use thereof
PCT/NL2013/050538 WO2014014348A1 (en) 2012-07-16 2013-07-15 Gastro-retentive drug delivery system

Publications (1)

Publication Number Publication Date
MX2015000760A true MX2015000760A (es) 2015-09-10

Family

ID=49162197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000760A MX2015000760A (es) 2012-07-16 2013-07-15 Sistema de suministro de farmaco gastro - retentivo.

Country Status (6)

Country Link
US (1) US20230115025A1 (es)
EP (1) EP2872140A1 (es)
AU (2) AU2013290875A1 (es)
CA (2) CA2879282C (es)
MX (1) MX2015000760A (es)
WO (1) WO2014014348A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CN116370644A (zh) 2014-06-11 2023-07-04 麻省理工学院 驻留结构及相关方法
EP3288604B1 (en) 2015-05-01 2021-11-17 Massachusetts Institute of Technology Triggerable shape memory induction devices
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
EP4302817A3 (en) 2015-12-08 2024-02-21 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
WO2017205844A2 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
WO2018064630A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2021176361A1 (en) * 2020-03-02 2021-09-10 Craft Health Pte Ltd Method of manufacturing oral dosage forms for extended drug release
CN112245399B (zh) * 2020-10-29 2023-02-28 西南医科大学 一种二氢杨梅素胃漂浮丸剂及其制备方法
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
WO2023166225A1 (en) * 2022-03-04 2023-09-07 APET Holding B.V. Digestive enzyme formulations
WO2023166224A1 (en) * 2022-03-04 2023-09-07 APET Holding B.V. Gastroretentive formulations containing protein or peptide
WO2023203008A1 (en) * 2022-04-21 2023-10-26 Conaris Research Institute Ag Oral composition comprising nicotinamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (es) * 1974-03-12 1980-04-02
JPH082781B2 (ja) * 1988-10-18 1996-01-17 嘉明 川島 中空顆粒状医薬及びその製法
JP2012500230A (ja) * 2008-08-18 2012-01-05 北京天衡▲薬▼物研究院 胃内滞留薬物放出システム及びその製造方法と使用
EP2731609A1 (en) * 2011-07-14 2014-05-21 APeT Holding B.V. Nicotinamide compositions and the therapeutic use thereof

Also Published As

Publication number Publication date
EP2872140A1 (en) 2015-05-20
CA2879282C (en) 2022-05-03
AU2018202652A1 (en) 2018-05-10
CA3149459A1 (en) 2014-01-23
US20230115025A1 (en) 2023-04-13
WO2014014348A1 (en) 2014-01-23
AU2013290875A1 (en) 2015-02-05
CA2879282A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
MX2015000760A (es) Sistema de suministro de farmaco gastro - retentivo.
EP3441468A3 (en) Delivery methods and compositions for nuclease-mediated genome engineering
WO2012031124A3 (en) Drug formulations using water soluble antioxidants
GB2499739A (en) Plug and method of unplugging a seat
EP3273079A4 (en) Electromagnetically enabled active type dynamic gas bearing
WO2014074462A3 (en) Medical device delivery system and methods of delivering medical devices
MX2013014422A (es) Miembros y métodos de contacto de heridas.
WO2013179137A3 (en) Systems, methods and devices for embolic protection
AR088379A1 (es) Formulaciones de etanercept estabilizadas con iones metalicos
WO2013173789A3 (en) Antisense oligonucleotide compositions
WO2013037609A3 (de) Verfahren zur anpassung eines hydrolytischen enzyms an eine das hydrolytische enzym stabilisierende komponente
IN2014DN07483A (es)
FR2943988B1 (fr) Harpon d'ancrage par exemple d'un aeronef et systeme d'ancrage comportant un tel harpon.
WO2010118237A3 (en) Techniques for processing a substrate
MX2014016121A (es) Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.
WO2011032896A3 (de) Verkapselung unter verwendung von wachsartigen substanzen
WO2013006558A3 (en) Compositions and methods for treating skeletal myopathy
EP3373996A4 (en) METHODS AND SYSTEMS FOR THE PRODUCTION, USE AND ADMINISTRATION OF ACTIVATED STEM CELLS
GB2493226B (en) Semiconductor Structure comprising Source/Drain Region, Contact Hole and Method of Forming the Same.
EP3355395A4 (en) MEMBRANE ELECTRODE ARRANGEMENT FOR FUEL CELL, METHOD FOR THE MANUFACTURE THEREOF AND FUEL CELL SYSTEM THEREWITH
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
EP3669070A4 (en) INTEGRATED SYSTEM FOR OPTIMUM EXTRACTION OF DRIVEN TIDAL ENERGY HYDRAULIC LOAD WITH MINIMUM OR NO ADVERSE ENVIRONMENTAL EFFECTS
MX2016004328A (es) Inmunopotenciador.
ECSP12012316A (es) Un sistema de control de estacionamientos a traves de un sistema de un tercero
WO2011140305A3 (en) Method of producing pleurodesis